Upstream Bio Presents Results from a Dose Ranging Study of Verekitug (UPB-101) in Adults with Asthma at the American Thoracic Society International Conference

– In a multiple-ascending dose (MAD) study in patients with asthma, up to 54% reduction in fractional exhaled nitric oxide concentration (FENO) was observed with administration of verekitug, with treatment effects sustained up to 24 weeks after last dose –

– Verekitug displayed a favorable safety and tolerability profile without evidence of clinically meaningful immunogenicity over 32 weeks –

– Data to date support dosing intervals of 12 and 24 weeks in Phase 2 –

Excerpt from the Press Release:

WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) — Upstream Bio, Inc., a clinical-stage company focused on the development of verekitug, a potential first-in-class antagonist of the Thymic Stromal Lymphopoietin (TSLP) receptor that may deliver best-in-class efficacy for people with severe asthma and related diseases, today presented clinical data from its dose-ranging study of verekitug (UPB-101) in adults with asthma, at the American Thoracic Society International Conference being held in San Diego, CA.

In all doses of verekitug, a rapid and complete TSLP receptor (TSLPR) occupancy within 2 weeks after the first dose was observed, and in doses >100 mg, TSLPR occupancy was sustained for up to 24 weeks after the last dose. As a result, a substantial reduction of FENO within 2 weeks after the first dose was observed in all doses of verekitug. With 100 mg of verekitug, a 54% reduction of FENO from baseline that was sustained for up to 24 weeks after the last dose was observed. Similar rapid, substantial and sustained reductions were observed in blood eosinophils, a type of white blood cell found in increased numbers in many patients with asthma. FENO is an accepted biomarker for underlying Type 2 lung inflammation in patients with asthma; higher levels of FENO are associated with an increased risk for future asthma exacerbations.

Verekitug was well-tolerated at all dose levels tested; the most common treatment emergent adverse event was headaches.

Click the button below to read the entire Press Release:

Continue Reading The Press Release